# India Preclinical Imaging Market > India Preclinical Imaging Market Research Report By Product (Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, Photoacoustic Imaging System) and By Distribution Channel (Optical, Nuclear, CT Contrast Agents, MRI Contrast Agents) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.03% - **2024:** $ 248.5 Million - **2025:** $ 263.48 Million - **2035:** $ 473 Million - **Key Players:** Bruker (DE), PerkinElmer (US), Siemens Healthineers (DE), GE Healthcare (US), Fujifilm (JP), Miltenyi Biotec (DE), Thermo Fisher Scientific (US), Mediso (HU), Invicro (US) **Report ID:** MRFR/MED/48773-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-preclinical-imaging-market-50530 --- ## Market Summary ## **India Preclinical Imaging Market Overview** As per MRFR analysis, the India Preclinical Imaging Market Size was estimated at 231 (USD Million) in 2023. The India Preclinical Imaging Market Industry is expected to grow from 298.5(USD Million) in 2024 to 594.3 (USD Million) by 2035. The India Preclinical Imaging Market CAGR (growth rate) is expected to be around 6.46% during the forecast period (2025 - 2035) **Key India Preclinical Imaging Market Trends Highlighted** Significant developments are being observed in the India preclinical imaging market, primarily due to increased research activities in the life sciences sector and technological improvements. Preclinical imaging advancements are being fostered by increased government financing and programs like the "Atal Innovation Mission," which are encouraging medical technology research and development. The need for efficient research instruments is being driven by the rising incidence of chronic illnesses in India, which emphasizes the necessity of sophisticated preclinical imaging solutions in safety assessments and medication development.  Furthermore, chances to develop imaging modalities, including MRI, PET, and CT technologies especially suited for research applications, are being created via partnerships between academic institutions and pharmaceutical businesses. As researchers concentrate on preclinical studies to speed up the process of converting human medicines to clinical settings, recent market trends also reflect a surge in interest in small animal imaging. Research goals and funding allocations have been significantly impacted by the emergence of personalized medicine and the growing demand for non-invasive imaging methods.  The adoption of imaging devices that provide real-time data and higher resolution is also on the rise in India, improving the precision of study findings. Furthermore, new opportunities to better collect and use imaging data are being presented by the growth of biobanks and clinical research centers throughout India.Clinical trial success rates can be raised and translational research accelerated by this database and imaging technology integration. The preclinical imaging market in India has a bright future thanks to the country's changing preclinical research landscape and strong emphasis on incorporating cutting-edge imaging technology. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **India Preclinical Imaging Market Drivers** **Growing Investment in Research and Development Activities** The increasing investment in Research and Development (R&D) activities across India is a significant driver for the India Preclinical Imaging Market Industry. The Indian government has committed substantial funds to boost health research, with the Department of Biotechnology set to invest over 2,600 million USD in the upcoming years. This investment aims to enhance the capabilities of medical research, particularly in the fields of drug development and disease modeling. Recognizing the critical role of preclinical studies in these processes, organizations such as the Indian Council of Medical Research (ICMR) are developing initiatives and infrastructure to support advanced imaging technologies, which is expected to result in a deeper understanding of disease biology and more effective therapies. The robust R&D funding and infrastructure endeavors will likely propel advancements in preclinical imaging technologies, thereby benefiting the overall market growth. **Increase in Chronic Disease Burden** India is witnessing a significant rise in the burden of chronic diseases, such as cancer and cardiovascular diseases. With the National Cancer Registry Program, it has been reported that cancer cases in India are expected to rise by 25% by 2025, equating to approximately 1.5 million new cases annually. This increasing incidence of chronic illnesses necessitates innovative diagnostic tools like preclinical imaging techniques, which offer researchers and developers crucial insights into disease progression and treatment options. Organizations such as the Tata Memorial Centre are utilizing advanced preclinical imaging technologies to enhance their research and treatment methodologies, further driving the demand for these imaging solutions in India. **Rising Demand for Personalized Medicine** The concept of personalized medicine is gaining traction in India, driven by the need for tailored therapies based on individual genetic and metabolic profiles. The Indian government, through initiatives like the National Health Mission, is pushing for advancements in genomics and personalized treatment plans. The market for personalized medicine is anticipated to grow significantly, with a focus on developing preclinical imaging techniques that can efficiently assess individual responses to treatments. Investments from organizations such as Biocon and Cadila Healthcare into personalized therapies underline this trend, creating an increased necessity for sophisticated preclinical imaging in therapeutic development, ultimately stimulating growth in the India Preclinical Imaging Market Industry. **India Preclinical Imaging Market Segment Insights** **Preclinical Imaging Market Product Insights** The India Preclinical Imaging Market is a vital component in Research and Development, facilitating advancements in diagnostic capabilities and therapeutic interventions. Within this expansive sector, the product segment encompasses diverse imaging technologies, including Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, and Photoacoustic Imaging Systems. Optical Imaging stands out for its non-invasive nature, allowing real-time observation of biological processes.  It is a crucial tool in assessing treatment effectiveness and understanding disease mechanisms in vivo. Nuclear Imaging, meanwhile, plays a significant role in drug discovery and development, particularly in tracking drug distribution and metabolism within living organisms. Micro-MRI provides high-resolution images of small animal models, enabling researchers to visualize anatomical structures with precision, thus contributing to enhanced disease modeling and validation. Micro-ultrasound is noted for its ability to offer dynamic imaging capabilities that are vital in assessing real-time physiological processes.  In contrast, Micro-CT is instrumental for its high spatial resolution and 3D imaging capabilities, making it ideal for analyzing complex biological structures and understanding tumor development at micro levels. Photoacoustic Imaging Systems combine optical and ultrasound technologies, providing functional information about tissue that is particularly beneficial for studying tumor characteristics and vascular development. The various imaging modalities within the product segment of the India Preclinical Imaging Market not only underscore the technological advancements in medical research but also reflect a growing acknowledgment of their significance in improving healthcare outcomes.  Together, these technologies contribute to the comprehensive landscape of preclinical imaging, enabling more informed decision-making in therapeutic development and advancing the overall objectives of the healthcare industry in India. As the country continues to invest in infrastructure and innovation for preclinical studies, the product segment of the India Preclinical Imaging Market remains poised for growth, driven by the increasing need for effective imaging solutions across various research domains. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Preclinical Imaging Market Distribution Channel Insights** The Distribution Channel segment of the India Preclinical Imaging Market reveals a multifaceted landscape critical for facilitating the effective delivery of imaging solutions. This segment encompasses various channels through which preclinical imaging technologies are disseminated, including Optical, Nuclear, CT Contrast Agents, and MRI Contrast Agents. Optical imaging has gained traction due to its non-invasive nature and potential for real-time applications in research and diagnostics, making it a popular choice within laboratory settings.  Nuclear imaging plays a pivotal role in pharmacokinetic studies and biodistribution tracing, cementing its relevance in the burgeoning field of personalized medicine.On the other hand, CT Contrast Agents and MRI Contrast Agents are integral to enhancing image clarity and diagnostic precision, which significantly influences clinical outcomes. The growth of the pharmaceutical and biotechnology industries in India drives demand for these imaging modalities, as they are increasingly essential in Research and Development efforts.  Furthermore, the integration of these channels influences the accessibility of advanced imaging technologies, positioning them as vital components in preclinical studies and accelerating the development of novel therapeutics.Enhanced distribution strategies will likely impact the overall functionality and outreach of these imaging modalities, thereby shaping the future of preclinical imaging in India. **India Preclinical Imaging Market Key Players and Competitive Insights** The India Preclinical Imaging Market has been witnessing significant growth due to the increasing demand for innovative research and development in the fields of biotechnology and pharmaceutical industries. As the healthcare landscape evolves, preclinical imaging technologies are becoming indispensable for understanding complex biological processes and evaluating the efficacy of new drugs. With rising investments in research initiatives and collaborations among various stakeholders, there is a competitive environment shaping up in this market.  Companies are continuously striving to enhance their technological offerings, catering to the diverse needs of researchers and medical professionals. This evolving competitive landscape is characterized by strategic partnerships, advancements in imaging technology, and an ongoing focus on providing cost-effective and efficient solutions for preclinical research.Graham Health has established a notable presence in the India Preclinical Imaging Market by offering a strong portfolio of imaging solutions tailored to meet the demands of research institutions and pharmaceutical companies.  The company's strengths lie in its innovative imaging technologies and a commitment to delivering high-quality products that enable detailed visualization of biological systems. Graham Health's focus on customer-centric solutions and its ability to adapt to the rapidly changing market trends have further solidified its reputation among competitors. The company's robust research and development capabilities also demonstrate a willingness to invest in new technologies that enhance imaging accuracy and efficiency.  This allows researchers in India access to cutting-edge tools necessary for advancing their preclinical studies.PerkinElmer is another significant player in the India Preclinical Imaging Market, recognized for its comprehensive suite of products and services designed for preclinical applications. The company has a diverse range of imaging systems, including in vivo imaging modalities that cater to various research needs in pharmacology and toxicology.  PerkinElmer's market presence in India is bolstered by its commitment to innovation and the ongoing development of strategic partnerships with leading research organizations. Additionally, PerkinElmer has engaged in several mergers and acquisitions that enhance its technological expertise and expand its capabilities within the region. This strategic positioning allows PerkinElmer to deliver superior imaging solutions and streamline workflows for researchers, enabling them to achieve more reliable and reproducible results in their preclinical investigations. The company's strong focus on delivering high-quality imaging products, combined with its extensive support services, makes it a dominant force in the Indian preclinical imaging landscape. **Key Companies in the India Preclinical Imaging Market Include** **India Preclinical Imaging Market Industry Developments** In recent months, the India Preclinical Imaging Market has witnessed notable developments, particularly in the area of technological advancements and partnerships among key players. Graham Health announced its collaboration with Siemens Healthineers in September 2023 to enhance imaging modalities, targeting improved diagnostics. PerkinElmer expanded its presence in India earlier this year, focusing on providing integrated imaging solutions for preclinical research, indicating a strategic push toward innovation in the market. Notably, GE Healthcare and Philips Healthcare have been investing in Research and Development to create advanced imaging systems tailored to local research needs, thereby improving the overall efficacy of diagnostics in preclinical studies. In terms of mergers and acquisitions, there were discussions around Canon Medical Systems acquiring a stake in a domestic imaging startup in July 2023 to bolster its market position.The Indian government has also prioritized the healthcare infrastructure, with initiatives aimed at promoting technology integration in medical imaging.  This is expected to contribute significantly to the market's growth, with increased funding for healthcare and research facilitating a broader application of preclinical imaging technologies across the nation. **India Preclinical Imaging Market Segmentation Insights** ## Market Drivers ### Government Initiatives and Support The Indian government is actively promoting the preclinical imaging market through various initiatives aimed at enhancing research capabilities. Programs that provide funding and resources for research institutions are becoming more prevalent, thereby facilitating advancements in imaging technologies. The Department of Biotechnology and the Indian Council of Medical Research have launched schemes to support innovative research projects, which often include preclinical imaging components. This governmental backing is expected to bolster the market, as it encourages collaboration between academia and industry. Furthermore, the allocation of approximately $200 million for biotechnology research in the recent budget indicates a strong commitment to fostering growth in this sector, which is likely to benefit the preclinical imaging market significantly. ### Growth in Biopharmaceutical Research The rapid growth of the biopharmaceutical sector in India is positively impacting the preclinical imaging market. As more biopharmaceutical companies emerge, the need for advanced imaging techniques to evaluate drug efficacy and safety becomes increasingly critical. The market for biopharmaceuticals is projected to reach $50 billion by 2025, with a substantial portion of this investment directed towards preclinical studies. This trend suggests that the demand for imaging technologies, such as optical imaging and ultrasound, will rise correspondingly. The integration of imaging modalities in biopharmaceutical research not only enhances the understanding of drug mechanisms but also accelerates the development process, thereby driving the preclinical imaging market forward. ### Rising Demand for Non-Invasive Techniques The preclinical imaging market in India is experiencing a significant increase in demand for non-invasive imaging techniques. Researchers and pharmaceutical companies are increasingly recognizing the advantages of non-invasive methods, which allow for real-time monitoring of biological processes without the need for surgical interventions. This trend is particularly relevant in the context of drug development, where understanding the pharmacokinetics and pharmacodynamics of new compounds is crucial. The market for non-invasive imaging modalities, such as MRI and PET, is expected to grow at a CAGR of approximately 10% over the next five years. This growth is driven by the need for more efficient and ethical research practices, as well as the increasing complexity of disease models that require advanced imaging solutions. ### Emergence of Advanced Imaging Technologies The preclinical imaging market is being significantly influenced by the emergence of advanced imaging technologies. Innovations such as hybrid imaging systems, which combine modalities like PET/CT and SPECT/MRI, are gaining traction among researchers in India. These technologies offer enhanced resolution and sensitivity, allowing for more accurate assessments of biological processes. The increasing adoption of these advanced systems is expected to propel the market, as they provide comprehensive insights into disease mechanisms and treatment responses. Furthermore, the market for these advanced imaging technologies is anticipated to grow at a CAGR of around 12% over the next few years, reflecting the ongoing demand for improved imaging solutions in preclinical research. ### Collaboration Between Academia and Industry Collaboration between academic institutions and industry players is becoming a pivotal driver for the preclinical imaging market in India. Such partnerships facilitate the exchange of knowledge and resources, leading to the development of innovative imaging solutions tailored to specific research needs. Universities are increasingly partnering with biotech firms to leverage their expertise in imaging technologies, which enhances the overall research landscape. This collaborative approach is likely to result in the introduction of novel imaging techniques and applications, thereby expanding the market. The establishment of research consortia and joint ventures is expected to foster a more integrated ecosystem, ultimately benefiting the preclinical imaging market by accelerating the pace of innovation and application. ## Future Outlook The [Preclinical Imaging Market](https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365) in India is projected to grow at a 6.03% CAGR from 2025 to 2035, driven by technological advancements and increasing R&D investments. **New opportunities:** - Development of AI-driven imaging software solutions - Expansion of imaging services in contract research organizations - Partnerships with pharmaceutical companies for tailored imaging solutions By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product: Optical Imaging (Largest) vs. Nuclear Imaging (Fastest-Growing) In the India preclinical imaging market, Optical Imaging holds a significant market share due to its versatility and widespread application in biomedical research. This segment offers real-time imaging capabilities, making it a preferred choice among researchers. Conversely, Nuclear Imaging is gaining traction, emerging as the fastest-growing segment driven by advancements in radiopharmaceuticals and the demand for more precise diagnostics and research methodologies. The growth trends in this segment are attributed to the increasing investment in research and development by pharmaceutical companies and research institutions. Additionally, the rising incidence of chronic diseases boosts the demand for advanced imaging techniques. The advent of innovative technologies, such as hybrid modalities, also contributes to the accelerating growth, with Nuclear Imaging expected to expand rapidly in the coming years. Optical Imaging (Dominant) vs. Micro-CT (Emerging) Optical Imaging is currently the dominant force in the India preclinical imaging market, characterized by its ability to deliver high-resolution images and its adaptability to various imaging needs. It is commonly used in live animal imaging and cancer research. In contrast, Micro-CT is an emerging technology that offers enhanced structural imaging capabilities and is particularly valuable for detailed anatomical studies. The development of compact and affordable Micro-CT systems is making this imaging modality more accessible to research institutions. As researchers seek detailed insights into the microanatomy of tissues, Micro-CT is expected to see robust growth, complementing the established dominance of Optical Imaging. ### By Reagents: Optical (Largest) vs. MRI Contrast Agents (Fastest-Growing) Among the reagents in the India preclinical imaging market, Optical agents hold the largest share, driven by their widespread use in various imaging applications. They are favored for their versatility and effectiveness in producing high-resolution, real-time imaging results, attracting significant market interest. On the other hand, MRI Contrast Agents, while smaller in market share, are recognized as the fastest-growing segment, reflecting an increase in demand for advanced imaging techniques that allow for better tissue characterization and pathology detection. The growth trends in the reagents segment point toward a shift towards greater specificity in imaging. Optical agents continue to dominate due to their established market presence, but the exponential rise in research and clinical applications of MRI Contrast Agents is noteworthy. Factors driving this growth include technological advancements in imaging modalities, increased funding for research in preclinical studies, and a growing emphasis on early disease detection and diagnosis. These trends indicate a dynamically evolving landscape in the reagents market, with both established and emerging players vying for position. Optical (Dominant) vs. MRI Contrast Agents (Emerging) Optical reagents are characterized by their ability to offer rapid and precise imaging capabilities, making them essential in early-stage research and diagnostic applications. They dominate the market due to their extensive range of applications, ease of use, and cost-effectiveness. In contrast, MRI Contrast Agents, although they are in the emerging phase of the market, exhibit a strong growth trajectory, fueled by innovations in imaging technology and heightened interest in non-invasive diagnostic techniques. MRI Contrast Agents enhance the quality of MRI scans, leading to improved visualization of soft tissues, making them increasingly essential for oncology, neurology, and cardiology research. Together, these segments illustrate a robust pipeline of reagent development with a focus on improving imaging accuracy and efficacy. ## Competitive Benchmarking The preclinical imaging market in India is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for innovative imaging solutions. Key players such as Bruker (DE), PerkinElmer (US), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Bruker (DE) focuses on innovation, particularly in the development of high-resolution imaging systems, which positions it as a leader in the market. Meanwhile, PerkinElmer (US) emphasizes partnerships with research institutions to foster collaborative innovation, thereby expanding its product offerings and enhancing its competitive edge. Siemens Healthineers (DE) is actively pursuing digital transformation initiatives, integrating AI and machine learning into its imaging solutions, which not only improves efficiency but also enhances diagnostic accuracy.The business tactics employed by these companies reflect a concerted effort to optimize operations and adapt to local market conditions. For instance, localizing manufacturing and optimizing supply chains are prevalent strategies aimed at reducing costs and improving service delivery. The competitive structure of the market appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial, shaping the overall direction of the industry. In October Siemens Healthineers (DE) announced a strategic partnership with a leading Indian research institute to develop advanced imaging technologies tailored for local healthcare needs. This collaboration is expected to enhance Siemens' product portfolio while addressing specific regional challenges, thereby solidifying its market position. The strategic importance of this partnership lies in its potential to accelerate innovation and improve access to cutting-edge imaging solutions in India. In September PerkinElmer (US) launched a new preclinical imaging system designed to streamline the drug discovery process. This system integrates advanced imaging modalities, which could significantly reduce the time required for preclinical studies. The launch underscores PerkinElmer's commitment to innovation and its strategy to meet the evolving needs of the pharmaceutical industry, potentially increasing its market share in the preclinical imaging sector. In August Bruker (DE) expanded its operations in India by establishing a new manufacturing facility aimed at enhancing production capabilities for its imaging systems. This move not only signifies Bruker's long-term commitment to the Indian market but also reflects a broader trend of companies investing in local manufacturing to mitigate supply chain disruptions. The establishment of this facility will improve Bruker's responsiveness to market demands and strengthen its competitive position. As of November the preclinical imaging market is witnessing trends such as digitalization, sustainability, and the integration of AI technologies. These trends are reshaping the competitive landscape, with strategic alliances becoming increasingly vital for companies seeking to enhance their technological capabilities. The shift from price-based competition to a focus on innovation and reliability in supply chains is evident, suggesting that future competitive differentiation will hinge on the ability to deliver advanced, efficient, and sustainable imaging solutions. ## Recent News & Developments In recent months, the India Preclinical Imaging Market has witnessed notable developments, particularly in the area of technological advancements and partnerships among key players. Graham Health announced its collaboration with Siemens Healthineers in September 2023 to enhance imaging modalities, targeting improved diagnostics. PerkinElmer expanded its presence in India earlier this year, focusing on providing integrated imaging solutions for preclinical research, indicating a strategic push toward innovation in the market. Notably, GE Healthcare and Philips Healthcare have been investing in Research and Development to create advanced imaging systems tailored to local research needs, thereby improving the overall efficacy of diagnostics in preclinical studies. In terms of mergers and acquisitions, there were discussions around Canon Medical Systems acquiring a stake in a domestic imaging startup in July 2023 to bolster its market position.The Indian government has also prioritized the healthcare infrastructure, with initiatives aimed at promoting technology integration in medical imaging.  This is expected to contribute significantly to the market's growth, with increased funding for healthcare and research facilitating a broader application of preclinical imaging technologies across the nation. ## Report Scope | MARKET SIZE 2024 | 248.5(USD Million) | | --- | --- | | MARKET SIZE 2025 | 263.48(USD Million) | | MARKET SIZE 2035 | 473.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.03% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bruker (DE), PerkinElmer (US), Siemens Healthineers (DE), GE Healthcare (US), Fujifilm (JP), Miltenyi Biotec (DE), Thermo Fisher Scientific (US), Mediso (HU), Invicro (US) | | Segments Covered | Product, Reagents | | Key Market Opportunities | Advancements in imaging technologies enhance drug discovery and development in the preclinical imaging market. | | Key Market Dynamics | Technological advancements and regulatory changes drive growth in the preclinical imaging market in India. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the overall valuation of the preclinical imaging market in India in 2024?** A: The overall market valuation was $248.5 Million in 2024. **Q: What is the projected market valuation for the preclinical imaging market in India by 2035?** A: The projected valuation for 2035 is $473.0 Million. **Q: What is the expected CAGR for the preclinical imaging market in India during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period is 6.03%. **Q: Which companies are considered key players in the India preclinical imaging market?** A: Key players include Bruker, PerkinElmer, Siemens Healthineers, GE Healthcare, Fujifilm, Miltenyi Biotec, Thermo Fisher Scientific, Mediso, and Invicro. **Q: What are the main product segments in the India preclinical imaging market?** A: Main product segments include Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, and Photoacoustic Imaging Systems. **Q: What were the valuation ranges for Optical Imaging in the India preclinical imaging market?** A: The valuation range for Optical Imaging was $30.0 Million to $60.0 Million. **Q: How did the valuation for Micro-CT compare to other imaging modalities in 2024?** A: The valuation for Micro-CT ranged from $60.0 Million to $120.0 Million, indicating a strong position among imaging modalities. **Q: What is the valuation range for MRI Contrast Agents in the India preclinical imaging market?** A: The valuation range for MRI Contrast Agents was $128.5 Million to $233.0 Million. **Q: What is the significance of the Nuclear Imaging segment in the market?** A: The Nuclear Imaging segment had a valuation range of $40.0 Million to $80.0 Million, contributing notably to the overall market. **Q: How do the projected growth figures for the preclinical imaging market reflect future trends?** A: The projected growth figures suggest a robust expansion, with the market expected to reach $473.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-preclinical-imaging-market-50530*